Notizie sul Mercato Azionario
Ultime notizie finanziarie · Aggiornato Mag 23, 2026
Apple compie 50 anni: da startup in garage a gigante da 3,73 trilioni di dollari—Ecco quanto varrebbe un investimento di 1.000 dollari al suo IPO oggi
Apple Turns 50: From Garage Startup To $3.73 Trillion Giant—Here's How Much A $1,000 Investment At Its IPO Would Be Worth Today
The panelists generally agreed that Apple's current valuation and future growth prospects are uncertain, with significant risks and opportunities ahead.
Ho chiesto a ChatGPT di spiegarmi Ethereum come se avessi 12 anni
I Asked ChatGPT To Explain Ethereum to Me Like I’m 12
The panel discussion on Ethereum's investment thesis highlights significant competition from other chains, regulatory risks, and the need for further …
Keir Starmalade, qualcuno? La marmellata dovrà davvero essere rinominata nel Regno Unito?
Keir Starmalade, anyone? Will marmalade really have to be rebranded in UK?
The panel generally agrees that the marmalade labeling change is a non-event for major UK food companies, with some long-term …
‘Non esattamente Greggs’: i creator di TikTok mettono alla prova le panetterie ‘gentrificati’ di Londra
‘Not quite Greggs’: TikTok creators put London’s ‘gentrified’ bakeries to the test
The panel's net takeaway is that while these premium-priced, artisanal bakeries benefit from TikTok-driven visibility, their long-term resilience and profitability …
Goldman Sachs alza il suo obiettivo di prezzo su PVH Corp. (PVH) a $93 da $83
Goldman Sachs Raises its Price Target on PVH Corp. (PVH) to $93 from $83
The panelists had a mixed view on PVH's outlook, with some flagging risks like EMEA softness, reliance on margin expansion, …
Ascendis Pharma A/S (ASND) Riporta Dati Positivi dalla Settimana 52 dello Studio di Fase 2 New InsiGHTS
Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial
The panel discusses ASND's Week 52 Phase 2 data showing TransCon hGH's non-inferiority to daily somatropin, with YUVIWEL's EMA approval …
Wolfe Research avvia la copertura di BeOne Medicines AG (ONC) con rating Outperform.
Wolfe Research Initiates Coverage of BeOne Medicines AG (ONC) with Outperform Rating
The panel is neutral on BeOne Medicines (ONC), with concerns about Brukinsa's long-term margins due to generic competition and uncertainty …
Mizuho abbassa il suo Price Target su Autolus Therapeutics plc (AUTL) a $10 da $12
Mizuho Lowers its Price Target on Autolus Therapeutics plc (AUTL) to $10 from $12
The panelists debated AUTL's outlook, with some highlighting its strong Q4 results and potential for 2026 inflection, while others raised …
Galapagos NV (GLPG) Firma un Accordo con Gilead sugli Asset di Ouro Medicines
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets
GLPG's partnership with Gilead on gamgertamig provides a pipeline extension and potential near-to-mid-term catalyst, but the deal's true value lies …
RBC Capital Abbassa il suo Price Target su Bicycle Therapeutics plc (BCYC) a $7 da $11
RBC Capital Lowers its Price Target on Bicycle Therapeutics plc (BCYC) to $7 from $11
BCYC's one-time revenue from terminated partnerships masks a pivot away from zelenectide due to regulatory feedback, reducing near-term commercialization visibility. …
I Migliori ETF per Petrolio a $100 da Comprare Subito
The Best ETFs For $100 Oil To Buy Right Now
The panel consensus is that while $105 WTI is driven by geopolitical risks, it may not be sustained due to …
TD Cowen Aumenta il suo Price Target su Marex Group plc (MRX) a $66 da $61
TD Cowen Raises its Price Target on Marex Group plc (MRX) to $66 from $61
Panelists are divided on Marex Group (MRX). Bulls highlight record revenue beats and potential re-rating, while bears question the sustainability …